6-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K/A

(Amendment No. 1)

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2014

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                             .

EXPLANATORY NOTE

This Amendment No. 1 (the “Amendment”) to the Report of Foreign Private Issuer on Form 6-K (the “Original 6-K”), originally furnished by China Cord Blood Corporation (the “Company”) to the Securities and Exchange Commission on November 25, 2014, amends the Original 6-K to include an unaudited condensed consolidated statement of changes in equity, unaudited condensed consolidated statements of cash flows, notes to the unaudited condensed consolidated financial statements and the applicable interactive data file as Exhibit 101, which provides the unaudited condensed consolidated financial statements in XBRL (eXtensible business reporting language), and to provide for the incorporation by reference described below. No other changes have been made to the Original 6-K. This Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original 6-K.

This Amendment and each of the exhibits to this Amendment are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-191121 and No. 333-183143) of the Company.

This Amendment contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Amendment is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Amendment is filed, and the Company does not intend to update any of the forward-looking statements after the date this Amendment is filed to conform these statements to actual results, unless required by law.

The forward-looking statements included in this Amendment are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including revisions to China’s One Child Policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; compliance with restrictive debt covenants under the Company’s senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

2

Results of Operations and Financial Condition

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2014 of the Company.

3

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets

(Amounts expressed in thousands)

		March 31,	September 30,
	Note	2014	2014	2014
		RMB	RMB	US$
ASSETS
Current assets
Cash and cash equivalents		1,882,901	2,156,527	351,340
Accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB20,322; September 30, 2014: RMB23,691 (US$3,860))		95,273	110,412	17,988
Inventories		31,583	25,611	4,172
Prepaid expenses and other receivables		37,010	16,712	2,723
Debt issuance costs	5	3,616	3,608	588
Deferred tax assets		7,664	8,578	1,398
Total current assets		2,058,047	2,321,448	378,209
Property, plant and equipment, net	3	626,632	616,545	100,446
Non-current prepayments		208,894	208,429	33,957
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB42,703; September 30, 2014: RMB48,300 (US$7,869))		225,496	211,805	34,507
Inventories		48,385	54,062	8,808
Intangible assets, net		120,549	118,239	19,263
Available-for-sale equity securities		144,247	139,637	22,750
Other investment		189,129	189,129	30,813
Debt issuance costs	5	7,854	6,028	982
Deferred tax assets		1,789	2,648	431
Total assets		3,631,022	3,867,970	630,166
LIABILITIES
Current liabilities
Bank loan	4	60,000	60,000	9,775
Accounts payable		10,422	15,624	2,545
Accrued expenses and other payables		102,559	77,625	12,647
Deferred revenue		196,432	208,151	33,912
Amounts due to related parties		21,453	22,245	3,624
Income tax payable		2,571	7,202	1,173
Deferred tax liabilities		3,900	6,500	1,059
Total current liabilities		397,337	397,347	64,735
Convertible notes	5	777,753	797,227	129,884
Non-current deferred revenue		823,921	962,574	156,822
Other non-current liabilities		164,077	189,529	30,878
Deferred tax liabilities		27,938	27,331	4,453
Total liabilities		2,191,026	2,374,008	386,772

4

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets (Continued)

(Amounts expressed in thousands, except share data)

	March 31,		September 30,
	2014		2014		2014
	RMB		RMB		US$
EQUITY
Shareholders’ equity of China Cord Blood Corporation
Ordinary shares
-US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31 and September 30, 2014, respectively	50		50		8
Additional paid-in capital	798,221		798,221		130,046
Treasury stock, at cost (March 31 and September 30, 2014: 136,899 shares, respectively)	(2,815	)	(2,815	)	(459	)
Accumulated other comprehensive income	84,263		81,393		13,260
Retained earnings	555,323		612,308		99,756
Total equity attributable to China Cord Blood Corporation	1,435,042		1,489,157		242,611
Non-controlling interests	4,954		4,805		783
Total equity	1,439,996		1,493,962		243,394
Commitments and contingencies	—		—		—
Total liabilities and equity	3,631,022		3,867,970		630,166

See accompanying notes to the unaudited condensed consolidated financial statements.

5

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income

(Amounts expressed in thousands, except per share data)

		Three months ended September 30,						Six months ended September 30,
	Note	2013		2014				2013		2014
		RMB		RMB		US$		RMB		RMB		US$
Revenues		141,635		152,122		24,784		270,356		305,453		49,764
Direct costs		(27,360	)	(30,348	)	(4,944	)	(51,852	)	(60,124	)	(9,795	)
Gross profit		114,275		121,774		19,840		218,504		245,329		39,969
Operating expenses
Research and development		(2,310	)	(2,330	)	(380	)	(4,833	)	(4,829	)	(787	)
Sales and marketing		(27,633	)	(30,953	)	(5,043	)	(56,057	)	(62,696	)	(10,214	)
General and administrative		(28,042	)	(31,028	)	(5,055	)	(55,444	)	(60,174	)	(9,804	)
Total operating expenses		(57,985	)	(64,311	)	(10,478	)	(116,334	)	(127,699	)	(20,805	)
Operating income		56,290		57,463		9,362		102,170		117,630		19,164
Other expense, net
Interest income		4,312		4,704		766		8,494		8,970		1,461
Interest expense		(16,461	)	(25,209	)	(4,107	)	(31,219	)	(50,104	)	(8,163	)
Exchange gain/(loss)		69		(182	)	(30	)	(55	)	(2	)	—
Dividend income		—		—		—		8,722		1,196		195
Others		514		680		111		1,044		1,297		211
Total other expense, net		(11,566	)	(20,007	)	(3,260	)	(13,014	)	(38,643	)	(6,296	)
Income before income tax		44,724		37,456		6,102		89,156		78,987		12,868
Income tax expense	6	(19,706	)	(10,214	)	(1,664	)	(31,079	)	(22,151	)	(3,609	)
Net income		25,018		27,242		4,438		58,077		56,836		9,259
Net income attributable to non-controlling interests		(114	)	7		1		(267	)	149		24
Net income attributable to China Cord Blood Corporation’s shareholders		24,904		27,249		4,439		57,810		56,985		9,283
Net income per share:
Attributable to ordinary shares	7
- Basic		0.33		0.35		0.06		0.73		0.72		0.12
- Diluted		0.33		0.35		0.06		0.73		0.72		0.12
Other comprehensive income
-Net effect of foreign currency translation, net of nil tax		2,789		913		149		9,594		1,442		235
-Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax		59,220		(8,818	)	(1,437	)	83,558		(4,312	)	(703	)
Comprehensive income		87,027		19,337		3,150		151,229		53,966		8,791
Comprehensive income attributable to non-controlling interests		(114	)	7		1		(267	)	149		24
Comprehensive income attributable to China Cord Blood Corporation’s shareholders		86,913		19,344		3,151		150,962		54,115		8,815

See accompanying notes to the unaudited condensed consolidated financial statements.

6

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statement of Changes in Equity

(Amounts expressed in thousands, except share data)

	China Cord Blood Corporation shareholders
											Accumulated
	Share capital			Additional		Treasury stock					other					Non-
	No. of			paid-in		No. of					comprehensive			Retained		controlling			Total
	shares	Amount		capital		shares		Amount			income			earnings		interests			equity
		RMB		RMB				RMB			RMB			RMB		RMB			RMB
Balance as of April 1, 2014	73,140,147	50		798,221		(136,899	)	(2,815		)	84,263			555,323		4,954			1,439,996
Net income	—	—		—		—		—			—			56,985		(149		)	56,836
Other comprehensive income	—	—		—		—		—			(2,870		)	—		—			(2,870		)
Balance as of September 30, 2014	73,140,147	50		798,221		(136,899	)	(2,815		)	81,393			612,308		4,805			1,493,962
Balance as of September 30, 2014 - US$		$	8	$	130,046			$	(459	)	$	13,260		$	99,756	$	783		$	243,394

See accompanying notes to the unaudited condensed consolidated financial statements.

7

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

(Amounts expressed in thousands)

	Six months ended September 30,
	2013		2014		2014
	RMB		RMB		US$
Cash flows from operating activities:
Net cash provided by operating activities	229,623		295,691		48,174
Cash flows from investing activities:
Purchase of property, plant and equipment	(57,069	)	(22,407	)	(3,651	)
Proceeds from disposal of property, plant and equipment	178		12		2
Net cash used in investing activities	(56,891	)	(22,395	)	(3,649	)
Cash flows from financing activities:
Repayments of bank loan	(50,000	)	(60,000	)	(9,775	)
Proceeds from bank loan	60,000		60,000		9,775
Payments for repurchase of shares	(4,422	)	—		—
Payments for debt issuance costs	(3,242	)	—		—
Net cash provided by financing activities	2,336		—		—
Effect of foreign currency exchange rate change on cash and cash equivalents	213		330		54
Net increase in cash and cash equivalents	175,281		273,626		44,579
Cash and cash equivalents at beginning of period	1,494,099		1,882,901		306,761
Cash and cash equivalents at end of period	1,669,380		2,156,527		351,340
Non-cash investing activities:
Payable for property, plant and equipment	14,789		—		—
Supplemental disclosures of cash flow information:
Cash paid for income taxes	30,888		23,680		3,858
Cash refund for income taxes	—		18,279		2,978
Cash paid for interest, net of capitalized interest	51,670		28,268		4,605

See accompanying notes to the unaudited condensed consolidated financial statements.

8

Notes to the unaudited condensed consolidated financial statements

(Amounts expressed in thousands, except share data)

1Principal activities and basis of presentation

(a)Principal activities

China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2014, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

(b)Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2014 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2014 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2014.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2014, the results of operations for the three and six months ended September 30, 2013 and 2014, and cash flows for the six months ended September 30, 2013 and 2014 have been made.

For the convenience of the readers, certain amounts as of and for the three and six months ended September 30, 2014 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.1380, being the spot exchange rate of U.S. dollars in effect on September 30, 2014 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2014 or at any other date.

9

2Summary of significant accounting policies

(a)Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

(b)Use of estimates

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the establishment of the selling prices of multiple deliverables in revenue arrangements, the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the valuation of property, plant and equipment, intangible assets and investment securities, the valuation allowances for receivables and deferred tax assets and the realizability of inventories.

3Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,		September 30,
	2014		2014		2014
	RMB		RMB		US$
Buildings	578,513		580,960		94,649
Leasehold improvements	14,864		14,864		2,422
Machineries	118,449		133,208		21,702
Motor vehicles	14,885		15,272		2,488
Furniture, fixtures and office equipment	35,433		38,558		6,282
Construction-in-progress	9,684		893		145
	771,828		783,755		127,688
Less: Accumulated depreciation	(145,196	)	(167,210	)	(27,242	)
Total property, plant and equipment, net	626,632		616,545		100,446

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2013 and 2014 was RMB7,560 and RMB12,146 (US$1,979), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2013 and 2014 was RMB14,998 and RMB22,398 (US$3,649), respectively.

As of March 31, 2014 and September 30, 2014, buildings with carrying value of RMB114,570 and RMB111,052 (US$18,093) were collateralized for a short-term bank loan of RMB60,000 and RMB60,000 (US$9,775) (see Note 4), respectively.

10

4Bank loan

On August 12, 2013, the Group borrowed RMB60,000 from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%. The Group repaid the bank loan in full on August 11, 2014.

On August 25, 2014, the Group borrowed RMB60,000 (US$9,775) from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%.

The bank loans are denominated in RMB and are collateralized by certain buildings of the Group (see Note 3).

5Convertible notes

The carrying amount of the convertible notes to KKR China Healthcare Investment Limited (“KKRCHIL”) (the “KKR Note”) and to Golden Meditech Holdings Limited (“GMHL”), which is a major shareholder of the Company, (the “GM Note”) (collectively the “Notes”), is summarized in the following table:

	March 31,	September 30,
	2014	2014	2014
	RMB	RMB	US$
Principal amount of the KKR Note	403,315	401,950	65,486
Principal amount of the GM Note	310,302	309,192	50,373
Cumulative interest payable	64,136	86,085	14,025
Carrying amount	777,753	797,227	129,884

The Company accrued interest on the Notes based on the guaranteed 12% internal rate of return per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the unaudited condensed consolidated balance sheets. Debt issuance costs capitalized in connection with the issuance of the Notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years.

In November 2014, GMHL completed the sale of the GM Note of US$50,000 in aggregate principal amount to Magnum Opus International Holdings Limited (“Magnum”), which is controlled by the Company’s chairman, and Cordlife Group Limited (“CGL”), for a total consideration of US$88,090. As a result, GMHL caused the Company to issue the note of US$25,000 in aggregate principal amount to each of Magnum and CGL. The GM Note was simultaneously cancelled. The Company, Magnum and CGL agreed to be bound by the terms of the registration rights agreement as though Magnum and CGL were original parties thereto.

Interest relating to the Notes was recognized as follows:

	Three months ended September 30,				Six months ended September 30,
	2013		2014		2013		2014
	RMB		RMB	US$	RMB		RMB	US$
KKR Note interest incurred	12,190		13,488	2,197	24,320		26,638	4,340
GM Note interest incurred	9,496		9,843	1,604	18,827		19,587	3,191
Amortization of debt issuance costs	912		912	149	1,819		1,814	295
Notes related interest cost capitalized	(6,600	)	—	—	(14,789	)	—	—
Total interest expense	15,998		24,243	3,950	30,177		48,039	7,826

11

6Income tax

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

In February 2012, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) received approval from the tax authority on the renewal of its High and New Technology Enterprise (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2013. Subject to reapplication, Beijing Jiachenhong’s HNTE status will enable it to the preferential income tax rate of 15% from January 1, 2014 to December 31, 2016. Management believes that Beijing Jiachenhong meets all the criteria required in connection with the reapplication of HNTE status and therefore applied 15% when recognizing current tax.

In June 2011, Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2010 to December 31, 2012. In April 2014, Guangzhou Nuoya received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2013 to December 31, 2015.

The new Enterprise Income Tax law and its implementation rules impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. During the period ended September 30, 2013, withholding tax of RMB6,000 was levied on dividends distributed by the Company’s PRC subsidiary to the holding company outside the PRC. As of March 31, 2014 and September 30, 2014, the Company has provided RMB3,900 and RMB6,500 (US$1,059), respectively, for withholding income tax on a portion of the undistributed earnings of its PRC subsidiaries according to management’s reinvestment plan. No income taxes were provided for the remaining undistributed earnings which are intended to be reinvested indefinitely in the PRC. As of September 30, 2014, such unremitted earnings that may be subject to the withholding tax amounted to RMB844,481 (US$137,582) and the related unrecognized deferred tax liability was RMB84,448 (US$13,758).

The Company’s effective income tax rates for the three months ended September 30, 2013 and 2014 were 44.1% and 27.3%, and were 34.9% and 28.0% for the six months ended September 30, 2013 and 2014, respectively. The effective income tax rates for the three and six months ended September 30, 2013 and 2014 differ from the PRC statutory income tax rate of 25% primarily due to the effect of Beijing Jiachenhong and Guangzhou Nuoya’s preferential tax treatments, which is offset by the effect of non-PRC entities not being subject to income tax, and the effect of withholding tax.

As of and for the six months ended September 30, 2014, the Company did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

12

7Net income per share

The following table sets forth the computation of basic net income per share and diluted net income per share for the three and six months ended September 30, 2013 and 2014 respectively:

		Three months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		24,904		27,249		4,439
Earnings allocated to participating convertible notes	(i)	(722	)	(1,638	)	(267	)
Net income for basic and diluted net income per share		24,182		25,611		4,172
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.33		0.35		0.06
- Diluted	(ii)	0.33		0.35		0.06

		Six months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		57,810		56,985		9,283
Earnings allocated to participating convertible notes	(i)	(4,417	)	(4,246	)	(692	)
Net income for basic and diluted net income per share		53,393		52,739		8,591
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.73		0.72		0.12
- Diluted	(ii)	0.73		0.72		0.12

Notes:

(i)The KKR Note and GM Note provide KKRCHIL and GMHL with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the Notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company’s shareholders is reduced by such allocated earnings to participating convertible notes for each reporting period in both basic and diluted net income per share computation.

(ii)During the three and six months ended September 30, 2013 and 2014, the Company had potentially dilutive ordinary shares of 40,521,495 respectively, representing shares issuable upon conversion of the Notes (see Note 5). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

13

Other Events

On November 25, 2014, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and six months ended September 30, 2014. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description
99.1 *	Press Release, dated November 25, 2014
101.INS XBRL	Instance Document
101.SCH XBRL	Taxonomy Extension Schema Document
101.CAL XBRL	Taxonomy Extension Calculation Linkbase Document
101.LAB XBRL	Taxonomy Extension Label Linkbase Document
101.PRE XBRL	Taxonomy Extension Presentation Linkbase Document

* Previously filed

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION
	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer
Dated: December 12, 2014

15

XML

Convertible notes (Details 3) (Convertible notes) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended			3 Months Ended			6 Months Ended			3 Months Ended			6 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 KKR Notes USD ($)	Sep. 30, 2014 KKR Notes CNY	Sep. 30, 2013 KKR Notes CNY	Sep. 30, 2014 KKR Notes USD ($)	Sep. 30, 2014 KKR Notes CNY	Sep. 30, 2013 KKR Notes CNY	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Sep. 30, 2013 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Sep. 30, 2013 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY
Debt Instrument
Notes interest incurred							$ 2,197	13,488	12,190	$ 4,340	26,638	24,320
Notes interest incurred													1,604	9,843	9,496	3,191	19,587	18,827
Amortization of debt issuance costs	149	912	912	295	1,814	1,819
Notes related interest cost capitalized			(6,600)			(14,789)
Total interest expense	$ 3,950	24,243	15,998	$ 7,826	48,039	30,177

XML

Summary of significant accounting policies

6 Months Ended

Sep. 30, 2014

Summary of significant accounting policies

Summary of significant accounting policies

2Summary of significant accounting policies

(a)Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

(b)Use of estimates

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the establishment of the selling prices of multiple deliverables in revenue arrangements, the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the valuation of property, plant and equipment, intangible assets and investment securities, the valuation allowances for receivables and deferred tax assets and the realizability of inventories.

XML

Principal activities and basis of presentation

6 Months Ended

Sep. 30, 2014

Principal activities and basis of presentation

Principal activities and basis of presentation

1Principal activities and basis of presentation

(a)Principal activities

China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2014, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

(b)Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2014 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2014 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2014.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2014, the results of operations for the three and six months ended September 30, 2013 and 2014, and cash flows for the six months ended September 30, 2013 and 2014 have been made.

For the convenience of the readers, certain amounts as of and for the three and six months ended September 30, 2014 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.1380, being the spot exchange rate of U.S. dollars in effect on September 30, 2014 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2014 or at any other date.

XML

Unaudited Condensed Consolidated Balance Sheets In Thousands, unless otherwise specified	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Mar. 31, 2014 CNY
Current assets
Cash and cash equivalents	$ 351,340	2,156,527	1,882,901
Accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB20,322; September 30, 2014: RMB23,691 (US$3,860))	17,988	110,412	95,273
Inventories	4,172	25,611	31,583
Prepaid expenses and other receivables	2,723	16,712	37,010
Debt issuance costs	588	3,608	3,616
Deferred tax assets	1,398	8,578	7,664
Total current assets	378,209	2,321,448	2,058,047
Property, plant and equipment, net	100,446	616,545	626,632
Non-current prepayments	33,957	208,429	208,894
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB42,703; September 30, 2014: RMB48,300 (US$7,869))	34,507	211,805	225,496
Inventories	8,808	54,062	48,385
Intangible assets, net	19,263	118,239	120,549
Available-for-sale equity securities	22,750	139,637	144,247
Other investment	30,813	189,129	189,129
Debt issuance costs	982	6,028	7,854
Deferred tax assets	431	2,648	1,789
Total assets	630,166	3,867,970	3,631,022
Current liabilities
Bank loan	9,775	60,000	60,000
Accounts payable	2,545	15,624	10,422
Accrued expenses and other payables	12,647	77,625	102,559
Deferred revenue	33,912	208,151	196,432
Amounts due to related parties	3,624	22,245	21,453
Income tax payable	1,173	7,202	2,571
Deferred tax liabilities	1,059	6,500	3,900
Total current liabilities	64,735	397,347	397,337
Convertible notes	129,884	797,227	777,753
Non-current deferred revenue	156,822	962,574	823,921
Other non-current liabilities	30,878	189,529	164,077
Deferred tax liabilities	4,453	27,331	27,938
Total liabilities	386,772	2,374,008	2,191,026
Shareholders' equity of China Cord Blood Corporation
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31 and September 30,2014, respectively	8	50	50
Additional paid-in capital	130,046	798,221	798,221
Treasury stock, at cost (March 31 and September 30, 2014: 136,899 shares, respectively)	(459)	(2,815)	(2,815)
Accumulated other comprehensive income	13,260	81,393	84,263
Retained earnings	99,756	612,308	555,323
Total equity attributable to China Cord Blood Corporation	242,611	1,489,157	1,435,042
Non-controlling interests	783	4,805	4,954
Total equity	243,394	1,493,962	1,439,996
Commitments and contingencies
Total liabilities and equity	$ 630,166	3,867,970	3,631,022

XML

Unaudited Condensed Consolidated Statement of Changes in Equity In Thousands, except Share data	Share capital USD ($)	Share capital CNY	Additional paid-in Capital USD ($)	Additional paid-in Capital CNY	Treasury stock USD ($)	Treasury stock CNY	Accumulated other comprehensive (loss)/income USD ($)	Accumulated other comprehensive (loss)/income CNY	Retained earnings USD ($)	Retained earnings CNY	Non-controlling interests USD ($)	Non-controlling interests CNY	Total USD ($)	Total CNY
Balance at Mar. 31, 2014		50		798,221		(2,815)		84,263		555,323		4,954		1,439,996
Balance, shares at Mar. 31, 2014		73,140,147				(136,899)								73,003,248
Net income										56,985		(149)	9,259	56,836
Other comprehensive income								(2,870)						(2,870)
Balance at Sep. 30, 2014	$ 8	50	$ 130,046	798,221	$ (459)	(2,815)	$ 13,260	81,393	$ 99,756	612,308	$ 783	4,805	$ 243,394	1,493,962
Balance, shares at Sep. 30, 2014	73,140,147				(136,899)								73,003,248

XML

Bank loan (Details) (Short-term bank loan) In Thousands, unless otherwise specified	0 Months Ended
	Aug. 25, 2014	Aug. 12, 2013	Aug. 25, 2014 USD ($)	Aug. 25, 2014 CNY	Aug. 12, 2013 CNY
Bank loan
Amount borrowed			$ 9,775	60,000	60,000
Term of the loan	1 year	1 year
Monthly fixed interest rate (as a percent)			0.60%	0.60%	0.60%

XML

Convertible notes (Details 2) (USD $) In Thousands, unless otherwise specified	1 Months Ended	6 Months Ended
	Nov. 30, 2014 Golden Meditech Holdings Limited (GMHL) Magnum And CGL Member	Sep. 30, 2014 Convertible notes	Nov. 30, 2014 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL)	Nov. 30, 2014 Convertible notes Magnum	Nov. 30, 2014 Convertible notes CGL
Debt Instrument
Guaranteed internal rate of return		12.00%
Aggregate principal amount			$ 50,000	$ 25,000	$ 25,000
Interest rate		7.00%
Consideration of sale of the GM Note	$ 88,090
Debt issuance costs, period amortized		5 years

XML

Unaudited Condensed Consolidated Statements of Cash Flows In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY
Cash flows from operating activities:
Net cash provided by operating activities	$ 48,174	295,691	229,623
Cash flows from investing activities:
Purchase of property, plant and equipment	(3,651)	(22,407)	(57,069)
Proceeds from disposal of property, plant and equipment	2	12	178
Net cash used in investing activities	(3,649)	(22,395)	(56,891)
Cash flows from financing activities:
Repayments of bank loan	(9,775)	(60,000)	(50,000)
Proceeds from bank loan	9,775	60,000	60,000
Payments for repurchase of shares			(4,422)
Payments for debt issuance costs			(3,242)
Net cash provided by financing activities			2,336
Effect of foreign currency exchange rate change on cash and cash equivalents	54	330	213
Net increase in cash and cash equivalents	44,579	273,626	175,281
Cash and cash equivalents at beginning of period	306,761	1,882,901	1,494,099
Cash and cash equivalents at end of period	351,340	2,156,527	1,669,380
Non-cash investing activities:
Payable for property, plant and equipment			14,789
Supplemental disclosures of cash flow information:
Cash paid for income taxes	3,858	23,680	30,888
Cash refund for income taxes	2,978	18,279
Cash paid for interest, net of capitalized interest	$ 4,605	28,268	51,670

XML

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Unaudited Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 3,860	23,691		20,322
Non-current accounts receivable, allowance for doubtful accounts	$ 7,869	48,300		42,703
Ordinary shares, par value per share	$ 0.0001		$ 0.0001
Ordinary shares, shares authorized	250,000,000	250,000,000	250,000,000	250,000,000
Ordinary shares, shares issued	73,140,147	73,140,147	73,140,147	73,140,147
Ordinary shares, shares outstanding	73,003,248	73,003,248	73,003,248	73,003,248
Treasury stock, shares	136,899	136,899	136,899	136,899

XML

Convertible notes (Tables)

6 Months Ended

Sep. 30, 2014

Convertible notes.

Schedule of Convertible Notes

	March 31,	September 30,
	2014	2014	2014
	RMB	RMB	US$
Principal amount of the KKR Note	403,315	401,950	65,486
Principal amount of the GM Note	310,302	309,192	50,373
Cumulative interest payable	64,136	86,085	14,025
Carrying amount	777,753	797,227	129,884

Schedule of Interest Relating to KKR Notes and GM Notes

	Three months ended September 30,				Six months ended September 30,
	2013		2014		2013		2014
	RMB		RMB	US$	RMB		RMB	US$
KKR Note interest incurred	12,190		13,488	2,197	24,320		26,638	4,340
GM Note interest incurred	9,496		9,843	1,604	18,827		19,587	3,191
Amortization of debt issuance costs	912		912	149	1,819		1,814	295
Notes related interest cost capitalized	(6,600	)	—	—	(14,789	)	—	—
Total interest expense	15,998		24,243	3,950	30,177		48,039	7,826

XML

Document and Entity Information	6 Months Ended
	Sep. 30, 2014
Document and Entity Information
Document Type	6-K/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 (the "Amendment") to the Report of Foreign Private Issuer on Form 6-K (the "Original 6-K"), originally furnished by China Cord Blood Corporation to the Securities and Exchange Commission on November 25, 2014, amends the Original 6-K to include an unaudited condensed consolidated statement of changes in equity, unaudited condensed consolidated statements of cash flows, notes to the unaudited condensed consolidated financial statements and the applicable interactive data file as Exhibit 101, which provides the unaudited condensed consolidated financial statements in XBRL (eXtensible business reporting language), and to provide for the incorporation by reference described below. No other changes have been made to the Original 6-K. This Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original 6-K.
Document Period End Date	Sep. 30, 2014
Entity Registrant Name	China Cord Blood Corp
Entity Central Index Key	0001467808
Trading Symbol	CO
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

XML

Net income per share (Tables)

6 Months Ended

Sep. 30, 2014

Net income per share

Schedule of Basic and Diluted Net Earnings Per Share

		Three months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		24,904		27,249		4,439
Earnings allocated to participating convertible notes	(i)	(722	)	(1,638	)	(267	)
Net income for basic and diluted net income per share		24,182		25,611		4,172
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.33		0.35		0.06
- Diluted	(ii)	0.33		0.35		0.06

		Six months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		57,810		56,985		9,283
Earnings allocated to participating convertible notes	(i)	(4,417	)	(4,246	)	(692	)
Net income for basic and diluted net income per share		53,393		52,739		8,591
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.73		0.72		0.12
- Diluted	(ii)	0.73		0.72		0.12

Notes:

(i) The KKR Note and GM Note provide KKRCHIL and GMHL with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the Notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company’s shareholders is reduced by such allocated earnings to participating convertible notes for each reporting period in both basic and diluted net income per share computation.

(ii) During the three and six months ended September 30, 2013 and 2014, the Company had potentially dilutive ordinary shares of 40,521,495 respectively, representing shares issuable upon conversion of the Notes (see Note 5). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

XML

Unaudited Condensed Consolidated Statements of Comprehensive Income In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			6 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY
Unaudited Condensed Consolidated Statements of Comprehensive Income
Revenues	$ 24,784	152,122	141,635	$ 49,764	305,453	270,356
Direct costs	(4,944)	(30,348)	(27,360)	(9,795)	(60,124)	(51,852)
Gross profit	19,840	121,774	114,275	39,969	245,329	218,504
Operating expenses
Research and development	(380)	(2,330)	(2,310)	(787)	(4,829)	(4,833)
Sales and marketing	(5,043)	(30,953)	(27,633)	(10,214)	(62,696)	(56,057)
General and administrative	(5,055)	(31,028)	(28,042)	(9,804)	(60,174)	(55,444)
Total operating expenses	(10,478)	(64,311)	(57,985)	(20,805)	(127,699)	(116,334)
Operating income	9,362	57,463	56,290	19,164	117,630	102,170
Other expense, net
Interest income	766	4,704	4,312	1,461	8,970	8,494
Interest expense	(4,107)	(25,209)	(16,461)	(8,163)	(50,104)	(31,219)
Exchange gain/(loss)	(30)	(182)	69		(2)	(55)
Dividend income				195	1,196	8,722
Others	111	680	514	211	1,297	1,044
Total other expense, net	(3,260)	(20,007)	(11,566)	(6,296)	(38,643)	(13,014)
Income before income tax	6,102	37,456	44,724	12,868	78,987	89,156
Income tax expense	(1,664)	(10,214)	(19,706)	(3,609)	(22,151)	(31,079)
Net income	4,438	27,242	25,018	9,259	56,836	58,077
Net income attributable to non-controlling interests	1	7	(114)	24	149	(267)
Net income attributable to China Cord Blood Corporation's shareholders	4,439	27,249	24,904	9,283	56,985	57,810
Net income per share: Attributable to ordinary shares
Basic	$ 0.06	0.35	0.33	$ 0.12	0.72	0.73
Diluted	$ 0.06	0.35	0.33	$ 0.12	0.72	0.73
Other comprehensive income
Net effect of foreign currency translation, net of nil tax	149	913	2,789	235	1,442	9,594
Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax	(1,437)	(8,818)	59,220	(703)	(4,312)	83,558
Comprehensive income	3,150	19,337	87,027	8,791	53,966	151,229
Comprehensive income attributable to non-controlling interests	1	7	(114)	24	149	(267)
Comprehensive income attributable to China Cord Blood Corporation's shareholders	$ 3,151	19,344	86,913	$ 8,815	54,115	150,962

XML

Convertible notes

6 Months Ended

Sep. 30, 2014

Convertible notes.

Convertible notes

5Convertible notes

The carrying amount of the convertible notes to KKR China Healthcare Investment Limited (“KKRCHIL”) (the “KKR Note”) and to Golden Meditech Holdings Limited (“GMHL”), which is a major shareholder of the Company, (the “GM Note”) (collectively the “Notes”), is summarized in the following table:

	March 31,	September 30,
	2014	2014	2014
	RMB	RMB	US$
Principal amount of the KKR Note	403,315	401,950	65,486
Principal amount of the GM Note	310,302	309,192	50,373
Cumulative interest payable	64,136	86,085	14,025
Carrying amount	777,753	797,227	129,884

The Company accrued interest on the Notes based on the guaranteed 12% internal rate of return per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the unaudited condensed consolidated balance sheets. Debt issuance costs capitalized in connection with the issuance of the Notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years.

In November 2014, GMHL completed the sale of the GM Note of US$50,000 in aggregate principal amount to Magnum Opus International Holdings Limited (“Magnum”), which is controlled by the Company’s chairman, and Cordlife Group Limited (“CGL”), for a total consideration of US$88,090. As a result, GMHL caused the Company to issue the note of US$25,000 in aggregate principal amount to each of Magnum and CGL. The GM Note was simultaneously cancelled. The Company, Magnum and CGL agreed to be bound by the terms of the registration rights agreement as though Magnum and CGL were original parties thereto.

Interest relating to the Notes was recognized as follows:

	Three months ended September 30,				Six months ended September 30,
	2013		2014		2013		2014
	RMB		RMB	US$	RMB		RMB	US$
KKR Note interest incurred	12,190		13,488	2,197	24,320		26,638	4,340
GM Note interest incurred	9,496		9,843	1,604	18,827		19,587	3,191
Amortization of debt issuance costs	912		912	149	1,819		1,814	295
Notes related interest cost capitalized	(6,600	)	—	—	(14,789	)	—	—
Total interest expense	15,998		24,243	3,950	30,177		48,039	7,826

XML

Bank loan

6 Months Ended

Sep. 30, 2014

Bank loan

Bank loan

4Bank loan

On August 12, 2013, the Group borrowed RMB60,000 from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%. The Group repaid the bank loan in full on August 11, 2014.

On August 25, 2014, the Group borrowed RMB60,000 (US$9,775) from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%.

The bank loans are denominated in RMB and are collateralized by certain buildings of the Group (see Note 3).

XML

Convertible notes (Details) (Convertible notes) In Thousands, unless otherwise specified	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Mar. 31, 2014 CNY	Sep. 30, 2014 KKR Notes USD ($)	Sep. 30, 2014 KKR Notes CNY	Mar. 31, 2014 KKR Notes CNY	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Sep. 30, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY
Debt Instrument
Principal amount of Notes				$ 65,486	401,950	403,315
Principal amount of Notes							50,373	309,192	310,302
Cumulative interest payable	14,025	86,085	64,136
Carrying amount	$ 129,884	797,227	777,753

XML

Principal activities and basis of presentation (Details)	Sep. 30, 2014 item
Principal activities and basis of presentation
Number of cord blood banking licenses issued that are held by the Company	3
Foreign currency convenience translation rate	6.1380

XML

Summary of significant accounting policies (Policy)

6 Months Ended

Sep. 30, 2014

Summary of significant accounting policies

Principles of consolidation

Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

Use of estimates

Use of estimates

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the establishment of the selling prices of multiple deliverables in revenue arrangements, the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the valuation of property, plant and equipment, intangible assets and investment securities, the valuation allowances for receivables and deferred tax assets and the realizability of inventories.

XML

Income tax

6 Months Ended

Sep. 30, 2014

Income tax

Income tax

6Income tax

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

In February 2012, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) received approval from the tax authority on the renewal of its High and New Technology Enterprise (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2013. Subject to reapplication, Beijing Jiachenhong’s HNTE status will enable it to the preferential income tax rate of 15% from January 1, 2014 to December 31, 2016. Management believes that Beijing Jiachenhong meets all the criteria required in connection with the reapplication of HNTE status and therefore applied 15% when recognizing current tax.

In June 2011, Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2010 to December 31, 2012. In April 2014, Guangzhou Nuoya received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2013 to December 31, 2015.

The new Enterprise Income Tax law and its implementation rules impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. During the period ended September 30, 2013, withholding tax of RMB6,000 was levied on dividends distributed by the Company’s PRC subsidiary to the holding company outside the PRC. As of March 31, 2014 and September 30, 2014, the Company has provided RMB3,900 and RMB6,500 (US$1,059), respectively, for withholding income tax on a portion of the undistributed earnings of its PRC subsidiaries according to management’s reinvestment plan. No income taxes were provided for the remaining undistributed earnings which are intended to be reinvested indefinitely in the PRC. As of September 30, 2014, such unremitted earnings that may be subject to the withholding tax amounted to RMB844,481 (US$137,582) and the related unrecognized deferred tax liability was RMB84,448 (US$13,758).

The Company’s effective income tax rates for the three months ended September 30, 2013 and 2014 were 44.1% and 27.3%, and were 34.9% and 28.0% for the six months ended September 30, 2013 and 2014, respectively. The effective income tax rates for the three and six months ended September 30, 2013 and 2014 differ from the PRC statutory income tax rate of 25% primarily due to the effect of Beijing Jiachenhong and Guangzhou Nuoya’s preferential tax treatments, which is offset by the effect of non-PRC entities not being subject to income tax, and the effect of withholding tax.

As of and for the six months ended September 30, 2014, the Company did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

XML

Net income per share

6 Months Ended

Sep. 30, 2014

Net income per share

Net income per share

7Net income per share

The following table sets forth the computation of basic net income per share and diluted net income per share for the three and six months ended September 30, 2013 and 2014  respectively:

		Three months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		24,904		27,249		4,439
Earnings allocated to participating convertible notes	(i)	(722	)	(1,638	)	(267	)
Net income for basic and diluted net income per share		24,182		25,611		4,172
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.33		0.35		0.06
- Diluted	(ii)	0.33		0.35		0.06

		Six months ended September 30,
	Note	2013		2014		2014
		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		57,810		56,985		9,283
Earnings allocated to participating convertible notes	(i)	(4,417	)	(4,246	)	(692	)
Net income for basic and diluted net income per share		53,393		52,739		8,591
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,003,248		73,003,248		73,003,248
Net income per share attributable to ordinary shares:
- Basic		0.73		0.72		0.12
- Diluted	(ii)	0.73		0.72		0.12

Notes:

(i) The KKR Note and GM Note provide KKRCHIL and GMHL with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the Notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company’s shareholders is reduced by such allocated earnings to participating convertible notes for each reporting period in both basic and diluted net income per share computation.

(ii) During the three and six months ended September 30, 2013 and 2014, the Company had potentially dilutive ordinary shares of 40,521,495 respectively, representing shares issuable upon conversion of the Notes (see Note 5). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

XML

Property, plant and equipment, net (Tables)

6 Months Ended

Sep. 30, 2014

Property, plant and equipment, net

Schedule of Property, Plant and Equipment, Net

	March 31,		September 30,
	2014		2014		2014
	RMB		RMB		US$
Buildings	578,513		580,960		94,649
Leasehold improvements	14,864		14,864		2,422
Machineries	118,449		133,208		21,702
Motor vehicles	14,885		15,272		2,488
Furniture, fixtures and office equipment	35,433		38,558		6,282
Construction-in-progress	9,684		893		145
	771,828		783,755		127,688
Less: Accumulated depreciation	(145,196	)	(167,210	)	(27,242	)
Total property, plant and equipment, net	626,632		616,545		100,446

XML

Property, plant and equipment, net (Details 2) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Mar. 31, 2014 CNY	Sep. 30, 2014 Buildings Short-term bank loan USD ($)	Sep. 30, 2014 Buildings Short-term bank loan CNY	Mar. 31, 2014 Buildings Short-term bank loan CNY
Property, Plant and Equipment [Line Items]
Carrying value of buildings collateralized for loans								$ 18,093	111,052	114,570
Depreciation expense	1,979	12,146	7,560	3,649	22,398	14,998
Bank loan	$ 9,775	60,000		$ 9,775	60,000		60,000	$ 9,775	60,000	60,000

XML

Income tax (Details) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended							6 Months Ended	45 Months Ended	27 Months Ended	57 Months Ended	15 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013	Sep. 30, 2014 CNY	Sep. 30, 2013	Sep. 30, 2014 PRC tax laws and rules	Sep. 30, 2013 PRC subsidiary CNY	Sep. 30, 2014 PRC subsidiary USD ($)	Sep. 30, 2014 PRC subsidiary CNY	Mar. 31, 2014 PRC subsidiary CNY	Sep. 30, 2014 PRC subsidiary PRC tax laws and rules CNY	Sep. 30, 2014 Beijing Jiachenhong	Dec. 31, 2016 Beijing Jiachenhong Scenario forecast	Sep. 30, 2014 Guangzhou Nuoya	Dec. 31, 2015 Guangzhou Nuoya Scenario forecast
Income Tax
Statutory income tax rate						25.00%
HNTE preferential tax rate												15.00%	15.00%	15.00%	15.00%
Withholding tax rate						10.00%
Withholding tax amount on dividends							6,000
Provision for income taxes on undistributed earnings											0
Provision for withholding tax								1,059	6,500	3,900
Effective income tax rate	27.30%	27.30%	44.10%	28.00%	34.90%
Unremitted earnings that may be subject to the withholding tax	137,582	844,481		844,481
Unrecognized deferred tax liability from unremitted earnings of PRC subsidiaries	13,758	84,448		84,448
Interest and penalties related to unrecognized tax benefits				0

XML

Unaudited Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (CNY) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Net effect of foreign currency translation, tax	0	0	0	0
Net unrealized gain/(loss) in available-for-sale equity securities, tax	0	0	0	0

XML

Property, plant and equipment, net

6 Months Ended

Sep. 30, 2014

Property, plant and equipment, net

Property, plant and equipment, net

3Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,		September 30,
	2014		2014		2014
	RMB		RMB		US$
Buildings	578,513		580,960		94,649
Leasehold improvements	14,864		14,864		2,422
Machineries	118,449		133,208		21,702
Motor vehicles	14,885		15,272		2,488
Furniture, fixtures and office equipment	35,433		38,558		6,282
Construction-in-progress	9,684		893		145
	771,828		783,755		127,688
Less: Accumulated depreciation	(145,196	)	(167,210	)	(27,242	)
Total property, plant and equipment, net	626,632		616,545		100,446

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2013 and 2014 was RMB7,560 and RMB12,146 (US$1,979), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2013 and 2014 was RMB14,998 and RMB22,398 (US$3,649), respectively.

As of March 31, 2014 and September 30, 2014, buildings with carrying value of RMB114,570 and RMB111,052 (US$18,093) were collateralized for a short-term bank loan of RMB60,000 and RMB60,000 (US$9,775) (see Note 4), respectively.

XML

Net income per share (Details) In Thousands, except Share data, unless otherwise specified	3 Months Ended			6 Months Ended			3 Months Ended			6 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Sep. 30, 2013 CNY	Sep. 30, 2014 Convertible notes USD ($)	Sep. 30, 2014 Convertible notes CNY	Sep. 30, 2013 Convertible notes CNY	Sep. 30, 2014 Convertible notes USD ($)	Sep. 30, 2014 Convertible notes CNY	Sep. 30, 2013 Convertible notes CNY
Net income per share
Interest rate							7.00%	7.00%		7.00%	7.00%
Numerator:
Net income attributable to the Company's shareholders	$ 4,439	27,249	24,904	$ 9,283	56,985	57,810
Earnings allocated to participating convertible notes							(267)	(1,638)	(722)	(692)	(4,246)	(4,417)
Net income for basic and diluted net income per share	$ 4,172	25,611	24,182	$ 8,591	52,739	53,393
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share	73,003,248	73,003,248	73,003,248	73,003,248	73,003,248	73,003,248
Net income per share attributable to ordinary shares:
Basic	$ 0.06	0.35	0.33	$ 0.12	0.72	0.73
Diluted	$ 0.06	0.35	0.33	$ 0.12	0.72	0.73
Anti-dilutive ordinary shares							40,521,495	40,521,495	40,521,495	40,521,495	40,521,495	40,521,495

XML

Property, plant and equipment, net (Details) In Thousands, unless otherwise specified	Sep. 30, 2014 USD ($)	Sep. 30, 2014 CNY	Mar. 31, 2014 CNY	Sep. 30, 2014 Buildings USD ($)	Sep. 30, 2014 Buildings CNY	Mar. 31, 2014 Buildings CNY	Sep. 30, 2014 Leasehold Improvements USD ($)	Sep. 30, 2014 Leasehold Improvements CNY	Mar. 31, 2014 Leasehold Improvements CNY	Sep. 30, 2014 Machineries USD ($)	Sep. 30, 2014 Machineries CNY	Mar. 31, 2014 Machineries CNY	Sep. 30, 2014 Motor Vehicles USD ($)	Sep. 30, 2014 Motor Vehicles CNY	Mar. 31, 2014 Motor Vehicles CNY	Sep. 30, 2014 Furniture, Fixtures and Office Equipment USD ($)	Sep. 30, 2014 Furniture, Fixtures and Office Equipment CNY	Mar. 31, 2014 Furniture, Fixtures and Office Equipment CNY	Sep. 30, 2014 Construction-in-Progress USD ($)	Sep. 30, 2014 Construction-in-Progress CNY	Mar. 31, 2014 Construction-in-Progress CNY
Property, Plant and Equipment
Property, plant and equipment	$ 127,688	783,755	771,828	$ 94,649	580,960	578,513	$ 2,422	14,864	14,864	$ 21,702	133,208	118,449	$ 2,488	15,272	14,885	$ 6,282	38,558	35,433	$ 145	893	9,684
Less: Accumulated depreciation	(27,242)	(167,210)	(145,196)
Total property, plant and equipment, net	$ 100,446	616,545	626,632